These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1065 related items for PubMed ID: 21119648

  • 1. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
    Liu BC, He L, He G, He Y.
    J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
    [Abstract] [Full Text] [Related]

  • 2. [Authorization and reimbursement of orphan drugs in an international comparison].
    Roll K, Stargardt T, Schreyögg J.
    Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
    [Abstract] [Full Text] [Related]

  • 3. Drugs for rare diseases: mixed assessment in Europe.
    Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Orphan drugs].
    Kolár J, Chalabala M, Srámková H.
    Ceska Slov Farm; 2001 Mar; 50(2):59-65. PubMed ID: 11288591
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Access to orphan drugs in Europe: current and future issues.
    Michel M, Toumi M.
    Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):23-9. PubMed ID: 22280193
    [Abstract] [Full Text] [Related]

  • 9. Developing treatments for inborn errors: incentives available to the clinician.
    Haffner ME.
    Mol Genet Metab; 2004 Apr; 81 Suppl 1():S63-6. PubMed ID: 15050976
    [Abstract] [Full Text] [Related]

  • 10. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity?
    Wellman-Labadie O, Zhou Y.
    Health Policy; 2010 May; 95(2-3):216-28. PubMed ID: 20036435
    [Abstract] [Full Text] [Related]

  • 11. The impact of the Orphan Drug Act on the development and advancement of neurological products for rare diseases: a descriptive review.
    Burke KA, Freeman SN, Imoisili MA, Coté TR.
    Clin Pharmacol Ther; 2010 Oct; 88(4):449-53. PubMed ID: 20856241
    [Abstract] [Full Text] [Related]

  • 12. Rare diseases, orphan drugs, and orphaned patients.
    Scheindlin S.
    Mol Interv; 2006 Aug; 6(4):186-91. PubMed ID: 16960139
    [No Abstract] [Full Text] [Related]

  • 13. [Orphan drugs: availability, reliability and reimbursement].
    Kreeftmeijer-Vegter AR, van Veldhuizen CK, de Vries PJ.
    Ned Tijdschr Geneeskd; 2012 Aug; 156(17):A4252. PubMed ID: 22531041
    [Abstract] [Full Text] [Related]

  • 14. R&D policy, agency costs and innovation in personalized medicine.
    Yin W.
    J Health Econ; 2009 Sep; 28(5):950-62. PubMed ID: 19671480
    [Abstract] [Full Text] [Related]

  • 15. Issues surrounding orphan disease and orphan drug policies in Europe.
    Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S.
    Appl Health Econ Health Policy; 2010 Sep; 8(5):343-50. PubMed ID: 20804226
    [Abstract] [Full Text] [Related]

  • 16. Regulators adopt more orphan drugs.
    Reardon S.
    Nature; 2014 Apr 03; 508(7494):16-7. PubMed ID: 24695293
    [No Abstract] [Full Text] [Related]

  • 17. The challenges of orphan drugs and orphan diseases: real and imagined.
    Hudson I, Breckenridge A.
    Clin Pharmacol Ther; 2012 Aug 03; 92(2):151-3. PubMed ID: 22814659
    [Abstract] [Full Text] [Related]

  • 18. Orphan drug legislation: lessons for neglected tropical diseases.
    Villa S, Compagni A, Reich MR.
    Int J Health Plann Manage; 2009 Aug 03; 24(1):27-42. PubMed ID: 18435430
    [Abstract] [Full Text] [Related]

  • 19. Orphan drug development: an economically viable strategy for biopharma R&D.
    Meekings KN, Williams CS, Arrowsmith JE.
    Drug Discov Today; 2012 Jul 03; 17(13-14):660-4. PubMed ID: 22366309
    [Abstract] [Full Text] [Related]

  • 20. Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations.
    Vegter S, Rozenbaum MH, Postema R, Tolley K, Postma MJ.
    Clin Ther; 2010 Aug 03; 32(9):1651-61. PubMed ID: 20974323
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 54.